Abstract:Abstract Purpose: Two viral oncoproteins, E6 and E7, are expressed in all human papillomavirus (HPV)–infected cells, from initial infection in the genital tract to metastatic cervical cancer. Intramuscular vaccination of women with high-grade cervical intraepithelial neoplasia (CIN2/3) twice with a naked DNA vaccine, pNGVL4a-sig/E7(detox)/HSP70, and a single boost with HPVE6/E7 recombinant vaccinia vaccine (TA-HPV) elicited systemic HPV-specific CD8 T-cell responses that could traffic to the lesion and was associated with regression in some patients (NCT00788164). Experimental Design: Here, we examine whether alteration of this vaccination regimen by administration of TA-HPV vaccination in the cervicovaginal tract, rather than intramuscular (IM) delivery, can more effectively recruit antigen-specific T cells in an orthotopic syngeneic mouse model of HPV16+ cervical cancer (TC-1 luc). Results: We found that pNGVL4a-sig/E7(detox)/HSP70 vaccination followed by cervicovaginal vaccination with TA-HPV increased accumulation of total and E7-specific CD8+ T cells in the cervicovaginal tract and better controlled E7-expressing cervicovaginal TC-1 luc tumor than IM administration of TA-HPV. Furthermore, the E7-specific CD8+ T cells in the cervicovaginal tract generated through the cervicovaginal route of vaccination expressed the α4β7 integrin and CCR9, which are necessary for the homing of the E7-specific CD8+ T cells to the cervicovaginal tract. Finally, we show that cervicovaginal vaccination with TA-HPV can induce potent local HPV-16 E7 antigen-specific CD8+ T-cell immune responses regardless of whether an HPV DNA vaccine priming vaccination was administered IM or within the cervicovaginal tract. Conclusions: Our results support future clinical translation using cervicovaginal TA-HPV vaccination. Clin Cancer Res; 22(3); 657–69. ©2015 AACR. See related commentary by Nizard et al., p. 530

Supplementary Figure 5 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8<sup>+</sup> T-cell–Mediated Tumor Control in the Genital Tract

Supplementary Figure 1 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8<sup>+</sup> T-cell–Mediated Tumor Control in the Genital Tract

Supplementary Figure 3 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell–Mediated Tumor Control in the Genital Tract

Local Hpv Recombinant Vaccinia Boost Following Priming with an Hpv Dna Vaccine Enhances Local Hpv-Specific Cd8(+) T-Cell-Mediated Tumor Control in the Genital Tract

HPV DNA vaccines expressing recombinant CRT/HPV6bE7 fusion protein inhibit tumor growth and angiogenic activity]

Supplementary figures 1-7 from Customized Viral Immunotherapy for HPV-Associated Cancer

A novel "priming-boosting" strategy for immune interventions in cervical cancer

The Ectopic Expression of Survivin T34A and FilC Can Enhance the Oncolytic Effects of Vaccinia Virus in Murine Gastric Cancer

One-prime Multi-Boost Strategy Immunization with Recombinant DNA, Adenovirus, and MVA Vector Vaccines Expressing HPV16 L1 Induces Potent, Sustained, and Specific Immune Response in Mice.

Enhanced Immunotherapeutic Effect of Modified HPV16 E7-pulsed Dendritic Cell Vaccine by an Adeno-Shrna-socs1 Virus

The humoral and cellular immune responses induced by HPV18L1-E6/E7 DNA vaccines in mice

Human HSP70 and Modified HPV16 E7 Fusion DNA Vaccine Induces Enhanced Specific CD8+ T Cell Responses and Anti-Tumor Effects.

Immune response induced in mice by attenuated Salmonella strain expressing HPV6b L1-E7 chimeric protein

Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway.

Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer

BMDCs Induce the Generation of the CD103+CD8+ Tissue-Resident Memory T Cell Subtype, Which Amplifies Local Tumor Control in the Genital Tract.

A Novel Dendritic Cell Targeting HPV16 E7 Synthetic Vaccine in Combination with PD-L1 Blockade Elicits Therapeutic Antitumor Immunity in Mice.

Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed

Supplementary Figure 4 from in Situ Vaccination with CD204 Gene-Silenced Dendritic Cell, Not Unmodified Dendritic Cell, Enhances Radiation Therapy of Prostate Cancer

Enhancing immunogenicity of HPV16 E7 DNA vaccine by conjugating codon-optimized GM-CSF to HPV16 E7 DNA

Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model

Supplementary Figure 5 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T-cell–Mediated Tumor Control in the Genital Tract

Supplementary Figure 1 from Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T-cell–Mediated Tumor Control in the Genital Tract